International Stem Cell Corporation (ISCO) – Flo
Post# of 124
Posted On: 01/13/2016 3:55:36 PM
International Stem Cell Corporation (ISCO) – Florey Clinical Service Agreement Expected to Deliver Results Later this Year
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, recently announced that it has entered into an agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct a Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson’s patients. The Florey is viewed by the medical community as one of the world’s leading brain research centers. With the largest neuroscience research team in Australia at its side, both parties’ collaborative efforts are now underway.
Director of the Movement Disorders Service at the Royal Melbourne Hospital, Dr. Andrew Evans, M.D., has assumed the duties that come with being named the study’s principal investigator. Dr. Evans has published extensively on Parkinson’s, addressing symptoms while leading several clinical research trials.
“We recently received authorization to initiate Phase I/IIa and now we are moving forward towards formal engagement of the clinical site to conduct this study. We are excited to work together with the Florey to conduct the clinical trials of ISC-hpNSC at the Royal Melbourne Hospital,” commented Russell Kern, PhD, executive vice president and chief scientific officer at International Stem Cell Corporation. “We expect to enroll all patients into the clinical trial in Q1 2016 and provide interim results in October 2016.”
ISC-hpNSC consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC are a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants.
ISCO’s resources and efforts are aimed at therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. Parthenogenesis, ISCO’s core technology, results in the creation of pluripotent human stem cells from unfertilized oocytes. hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. Company scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of various genders, ages and racial backgrounds with minimal immune rejection after transplantation.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, recently announced that it has entered into an agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct a Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson’s patients. The Florey is viewed by the medical community as one of the world’s leading brain research centers. With the largest neuroscience research team in Australia at its side, both parties’ collaborative efforts are now underway.
Director of the Movement Disorders Service at the Royal Melbourne Hospital, Dr. Andrew Evans, M.D., has assumed the duties that come with being named the study’s principal investigator. Dr. Evans has published extensively on Parkinson’s, addressing symptoms while leading several clinical research trials.
“We recently received authorization to initiate Phase I/IIa and now we are moving forward towards formal engagement of the clinical site to conduct this study. We are excited to work together with the Florey to conduct the clinical trials of ISC-hpNSC at the Royal Melbourne Hospital,” commented Russell Kern, PhD, executive vice president and chief scientific officer at International Stem Cell Corporation. “We expect to enroll all patients into the clinical trial in Q1 2016 and provide interim results in October 2016.”
ISC-hpNSC consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC are a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants.
ISCO’s resources and efforts are aimed at therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. Parthenogenesis, ISCO’s core technology, results in the creation of pluripotent human stem cells from unfertilized oocytes. hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. Company scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of various genders, ages and racial backgrounds with minimal immune rejection after transplantation.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
(0)
(0)